In the BioHarmony Drug Report Database

"Preview" Icon


Mycapssa, Sandostatin, Sandostatin Lar, SomaKit TOC (octreotide) is a protein pharmaceutical. Octreotide was first approved as Mycapssa on 1988-10-21. It is used to treat acromegaly, adenoma, diarrhea, pancreatic neoplasms, and pituitary neoplasms in the USA. It has been approved in Europe to treat neuroendocrine tumors and radionuclide imaging. The pharmaceutical is active against somatostatin receptor type 2. In addition, it is known to target somatostatin receptor type 3 and somatostatin receptor type 5. Sandostatin’s patents are valid until 2036-02-03 (FDA).


Trade Name


SomaKit TOC

Common Name








acromegaly, adenoma, diarrhea, neuroendocrine tumors, pancreatic neoplasms, pituitary neoplasms, radionuclide imaging

Drug Class


Peptides: inhibition of growth hormone release

Image (chem structure or protein)

Octreotide structure rendering